Joseph Woolley, MD
Internal Medicine · Saint George, UTNPI 1780800813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 627 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 627 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novartis$1K
- Pfizer$733
- Novo Nordisk$604
- Lilly USA, LLC$522
- plus $5K from 51 others
Across 1,060 payments — averaging $3356.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$807K
- Pfizer$760K
- Novo Nordisk AS$615K
- Amgen$459K
- Boehringer Ingelheim$311K
- Hoffmann-la Roche Limited$277K
- plus $329K from 5 others
What the payments were for
- Food & beverage$10,15399%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Strensiq$125
How this compares
$10,275 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 187 | $257,083 |
| JardianceEmpagliflozin | 83 | $145,111 |
| EliquisApixaban | 108 | $140,706 |
| OzempicSemaglutide | 103 | $130,014 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $105,422 |
| TrulicityDulaglutide | 53 | $83,987 |
| FarxigaDapagliflozin Propanediol | 50 | $62,722 |
| MyrbetriqMirabegron | 58 | $58,595 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $48,211 |
| XareltoRivaroxaban | 45 | $44,916 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $42,801 |
| LinzessLinaclotide | 48 | $38,334 |
| RybelsusSemaglutide | 17 | $38,011 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $28,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $26,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $522 | $341,070240 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $604 | $210,826136 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Glyxambi | $495 | $186,596124 claims |
| PfizerEliquis, Premarin | $733 | $144,124121 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $204 | $105,42258 claims |
| AstraZenecaFarxiga | $1,042 | $62,72250 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $58,59558 claims |
| Johnson & JohnsonXarelto | $291 | $44,91645 claims |
| AbbVieLinzess, Synthroid | $1,347 | $43,435134 claims |
| GSKTrelegy Ellipta | $131 | $26,64316 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $18,03832 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $219 | $15,20721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Saint George
- Richard BennettSaint George$5K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Barbara RizzardiSandy$30K
- Gerald GleichSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.